Will the Patient Protection and Affordable Care Act stifle medical innovations?

In March 2010, the United States Congress and President Obama passed the Patient Protection and Affordable Care Act (PPACA) [1] to contain America’s medical costs [2].  Although this law passed, it was not by a bipartisan measure [3], and many Republicans believed that the American healthcare care should have been left unaltered.4  However, most understood that the status quo was not a viable option.  American health care costs were over 16% of GDP in 2010 and expected to be over 20% by 2020 [4].  The PPACA puts costs on a more sustainable trajectory.

Continue reading Will the Patient Protection and Affordable Care Act stifle medical innovations?

Welcome to the Regulatory Affairs Views Blog!

Welcome!  My blog is a news blog for Regulatory Affairs (RA) and Medical Affairs (MA).  This RA and MA blog has three purposes:

  • To post opinions on relevant current topics and to obtain comments related to these issues.  My hope is to give us an opportunity get more involved in the regulations formed by our government that aid our medical industries to deliver safe and effective healthcare product to American providers and consumers.
  • To help the regulatory community and health care providers be informed on the new, generic, and biologic drug and medical device approvals by the Food and Drug Administration (FDA).
  • To help me become more familiar with RA and MA and to have a more positive impact on my career.

As some of you may already know, I was trained as a physician, specifically in Anesthesiology and Pain Medicine. I went back to school and received a Masters Degree in Regulatory Affairs for Pharmaceuticals, Medical Devices and Biologics from Northeastern University.

I hope you enjoy this blog!

Zarina G. Memon, MD, MS


News and opinions on Medicine and Regulation